newsfilter
← Latest News
Business Wire·

Afya Limited Announces Third Quarter and Nine Months 2025 Financial Results

AFYA
  • Afya Limited reported 3Q25 revenue of R$928.5 million (up 10.4% YoY) & 9M25 revenue of R$2,784.3 million (up 13.4% YoY), with revenue excluding acquisitions growing 10.1% & 9.8% respectively.
  • Adjusted EBITDA for 3Q25 reached R$398.9 million (up 14.6% YoY) with a margin of 43.0%, while 9M25 Adjusted EBITDA totaled R$1,291.7 million (up 18.5% YoY) with a margin of 46.4%.
  • Net income increased 28.4% YoY to R$159.4 million in 3Q25 & 19.9% YoY to R$593.0 million in 9M25; Adjusted Net Income grew 16.5% & 11.1% respectively.
  • Basic EPS for 9M25 was R$6.40, representing a 19.7% increase YoY, while the Operating Cash Conversion Ratio reached 101.5%.
  • The company reaffirmed its full-year 2025 guidance: Revenue between R$3,670 million & R$3,770 million, Adjusted EBITDA between R$1,620 million & R$1,720 million, & CAPEX between R$250 million & R$290 million.
  • Cash & Cash Equivalents stood at R$996.8 million as of September 30, 2025, while Net Debt (excluding IFRS 16) decreased 26.0% YoY to R$1,342.2 million.
  • In October 2025, Afya issued R$1.5 billion in commercial notes maturing in 2028 & 2030 to refinance debt & extend duration.
  • On November 3, 2025, Afya repurchased all 150,000 Series A perpetual convertible preferred shares from SoftBank for R$831.6 million & cancelled them.
  • On November 7, 2025, the Brazilian Ministry of Education (MEC) authorized an increase of 100 medical school seats at ITPAC Porto, bringing the campus total to 150 seats.
  • The Afya ecosystem reached approximately 304,000 users, with Undergraduate programs showing strong student growth & Medical Practice Solutions increasing active payers in Clinical Management.
  • A new share repurchase program approved in August 2025 allows for the buyback of up to 4,000,000 Class A common shares through December 31, 2026.